# Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

> **NCT00055861** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** docetaxel
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00055861
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2006-08
- **Final completion:** —
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00055861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00055861, "Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00055861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*